Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01985854
Other study ID # TIVA DES conversion
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received October 7, 2013
Last updated November 9, 2013
Start date January 2014

Study information

Verified date November 2013
Source Tokyo Women's Medical University
Contact Makoto Ozaki, Ph.D
Phone 81-3-3353-8111
Email mozaki@anes.twmu.ac.jp
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

Since neurological testing during neurosurgery, such as somato-sensory evoked potentials, motor-evoked potentials, auditory evoked potentials and visual evoked potentials are well maintained their wave-form reactivity with total intravenous anaesthesia technique better than inhalational anesthetic techniques, the standard anesthesia method for neurosurgery is usually total intravenous anaesthesia technique. Nonetheless, after finishing recording the evoked potential responses during surgery, facilitation of recovery from general anesthesia is getting important, because the real neurological physical examination is much more sensitive than above electrical evoked potentials to evaluate the results of surgical operation.

We propose to evaluate the recovery parameters after conversion from total intravenous anaesthesia technique to Desflurane anesthesia during long term neurosurgery procedures. The conversion will be initiated upon completion of the neurophysiological electric evoked potentials assessment. Based on the pharmacological properties of desflurane, we hypothesize that recovery after conversion to Desflurane will be faster compared to recovery after total intravenous anaesthesia alone.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients undergoing elective craniotomy

- American Society of Anesthesiology Physical Status ?, II and III

- Age: between 20 to 65 years

- Sex: male or female

- Patients who are postmenopausal or surgically sterilized

- Expected Operation time is longer than 4 hours.

Exclusion Criteria:

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Patients Undergoing Elective Craniotomy

Intervention

Drug:
Propofol

Desflurane


Locations

Country Name City State
Japan Tokyo Women's Medical University Hospital Tokyo

Sponsors (2)

Lead Sponsor Collaborator
Tokyo Women's Medical University Baxter Healthcare Corporation

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Other Length of ICU stay Patients will be followed for the duration of intensive care unit stay, an expected average of 1 week No
Primary Time from the discontinuation of anesthesia to extubation Patients will be followed in the operation room, an expected average of 30 minutes. No
Secondary Time from the discontinuation of anesthesia to eye opening At the end of surgery, duration time from the discontinuation of anesthesia to the eye opening will be measured, averaged expected time is 30 minutes No
Secondary Cognitive function Cognitive function will be measured by Mini-Mental state examination at baseline (preoperatively) 5 minutes and 24 hours after extubation. Postoperative recovery function will be also measured by Post-operative Quality Recovery Scale (PQRS scale) at 5 minutes and 24 hours after extubation. Up to 24 hours No
Secondary Time from the discontinuation of anesthesia to orientation Time from the discontinuation of anesthesia to orientation (State name, state the date of birth) Up to 24 hours No
See also
  Status Clinical Trial Phase
Recruiting NCT06031883 - Efficacy of Adding Low Dose Ketamine or Fentanyl to Propofol-dexmedetomidine as Total Intravenous Anesthesia Phase 1/Phase 2